Molecular Determinants of Glioblastoma Response to EGFR Kinase Inhibitors
Author Information
Author(s): Komotar Ricardo J., Otten Marc L., Merkow Maxwell B., Bruce Jeffrey N.
Primary Institution: Columbia University
Hypothesis
Can the presence of specific molecular markers predict the response of glioblastoma patients to EGFR kinase inhibitors?
Conclusion
The presence of EGFRvIII and PTEN may serve as predictive markers for treatment success in glioblastoma patients receiving EGFR kinase inhibitors.
Supporting Evidence
- Twenty-seven percent of patients responded to EGFR-ki therapy by showing tumor shrinkage of at least 25%.
- Coexpression of EGFRvIII and PTEN was significantly associated with clinical responsiveness.
- These findings were validated in 33 GBM patients undergoing similar treatment at a different institution.
Takeaway
Doctors can use certain markers in glioblastoma tumors to help decide which treatments will work best for patients.
Methodology
The study sequenced the kinase domains of EGFR and Her2/neu and analyzed the expression of EGFR, EGFRvIII, and PTEN in recurrent malignant gliomas from patients receiving EGFR kinase inhibitor therapy.
Limitations
The study was limited to a small sample size and specific patient population.
Participant Demographics
Patients with recurrent malignant gliomas, specifically those receiving EGFR kinase inhibitor therapy.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website